Statement: Patients with metastatic HER-2-negative adenocarcinoma of the breast may be eligible for the primary trial.
Primary_evidence: DISEASE CHARACTERISTICS:   Histologically or cytologically confirmed primary adenocarcinoma of the breast   Locally recurrent or metastatic disease   Must have HER-2-negative breast cancer or, if HER-2-positive, must be unable to receive trastuzumab (Herceptin®) or have previously received trastuzumab in the past   Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm by conventional techniques or as > 10 mm by spiral CT scan.   No known CNS disease   Hormone receptor status not specified   PATIENT CHARACTERISTICS: Inclusion criteria:   Postmenopausal status not specified   ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%   Life expectancy > 12 weeks   WBC  3,000/mcL   Absolute neutrophil count  1,500/mcL   Platelet count  100,000/mcL   Total bilirubin normal   AST and ALT  2.5 times upper limit of normal (ULN)   Alkaline phosphatase  2.5 times ULN (unless bone metastasis is present in the absence of liver metastasis)   Creatinine  1.5 mg/dL   Not pregnant or nursing   Negative pregnancy test   Fertile patients must use effective contraception   No other concurrent malignancies within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix Exclusion criteria:   Pre-existing neuropathy  grade 1   Uncontrolled intercurrent illness including, but not limited to, any of the following:   Ongoing or active infection   Symptomatic congestive heart failure   Unstable angina pectoris   Cardiac arrhythmia   Serious, non-healing wound, ulcer, or bone fracture   Psychiatric illness/social situations that would limit compliance with study requirements   Inadequately controlled hypertension (defined as systolic blood pressure > 150 mm Hg and/or diastolic blood pressure > 100 mm Hg on antihypertensive medications)   History of hypertensive crisis or hypertensive encephalopathy   New York Heart Association class II-IV congestive heart failure   History of myocardial infarction or unstable angina within the past 6 months   History of stroke or transient ischemic attack within the past 6 months   Significant vascular disease (e.g., aortic aneurysm, aortic dissection)   Symptomatic peripheral vascular disease   Evidence of bleeding diathesis or coagulopathy   Significant traumatic injury within the past 28 days   History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months   Proteinuria, as demonstrated by either urine protein:creatinine ratio  1.0 OR urine dipstick for proteinuria  2+   Patients discovered to have  2+ proteinuria on dipstick urinalysis at baseline must demonstrate 24-hour urine protein  1g   History of allergy or hypersensitivity to paclitaxel albumin-stabilized nanoparticle formulation, paclitaxel, bevacizumab, carboplatin, albumin, drug product excipients, or chemically similar agents   PRIOR CONCURRENT THERAPY:   See Disease Characteristics   Recovered from all prior therapy   No prior chemotherapy for locally recurrent or metastatic disease   Prior neoadjuvant or adjuvant chemotherapy allowed   More than 1 week since prior core biopsy or other minor surgical procedure, excluding placement of a vascular access device   More than 4 weeks since prior and no concurrent major surgical procedure or open biopsy   More than 4 weeks since prior radiotherapy   More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)   At least 1 year since prior taxane regimen   No other concurrent investigational agents   Concurrent anticoagulation allowed, provided the following criteria are met:   Stable dose of warfarin or low molecular weight heparin   INR within desired range (2-3)   No evidence of active bleeding or coagulopathy   No concurrent combination antiretroviral therapy for HIV-positive patients   No other concurrent radiotherapy, chemotherapy, immunotherapy, or antitumor hormonal therapy